VKTXW - (Viking Therapeutics Inc.)

VKTXWのニュース

   Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK0214  2020/09/09 11:05:00 PR Newswire
SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 1 single ascending dose…
   Buy the Dip in Viking Therapeutics Stock, Says Analyst  2020/09/01 23:06:53 Yahoo Finance
Last week ended on a disappointing note for investors of NASH drug developer Viking Therapeutics (VKTX). Successive days in the red resulted in a cumulative share loss of 13%. The sell-off was instigated by two seemingly negative events.Firstly, Viking presented data from the Phase 2 study of VK2809
   Viking Therapeutics Presents New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress™ 2020  2020/08/28 10:00:00 PR Newswire
SAN DIEGO, Aug. 28, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of new results from the company's…
   Viking Therapeutics to Present New Data from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol at The Digital International Liver Congress™ 2020  2020/08/20 11:30:00 PR Newswire
SAN DIEGO, Aug. 20, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that data from the company's 12-week Phase 2 study of…
   Viking Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update  2020/07/29 20:05:00 PR Newswire
SAN DIEGO, July 29, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six…
   Viking Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update  2020/07/29 20:05:00 PR Newswire
SAN DIEGO, July 29, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six…
   Viking Therapeutics to Report Financial Results for Second Quarter 2020 on July 29, 2020  2020/07/22 20:05:00 PR Newswire
SAN DIEGO, July 22, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for…
   Viking Therapeutics Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting  2020/05/12 21:00:00 PR Newswire
SAN DIEGO, May 12, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced a change to its 2020 Annual Meeting of Stockholders….
   Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update  2020/04/30 20:05:00 PR Newswire
SAN DIEGO, April 30, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended…
   Viking Therapeutics to Report Financial Results for First Quarter 2020 on April 30, 2020  2020/04/23 11:30:00 PR Newswire
SAN DIEGO, April 23, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results…
   Viking Therapeutics to Report Financial Results for First Quarter 2020 on April 30, 2020  2020/04/23 11:30:00 PR Newswire
SAN DIEGO, April 23, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results…
   Viking Therapeutics to Participate in 19th Annual Needham Healthcare Conference  2020/04/07 11:30:00 PR Newswire
SAN DIEGO, April 7, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in the Needham &…
   The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More  2020/03/03 12:51:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 2) Forty Seven Inc (NASDAQ: FTSV )( announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD )) IGM Biosciences Inc (NASDAQ: IGMS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Karyopharm Therapeutics Inc (NASDAQ: KPTI )(announced positive late-stage results for selinexor) Passage Bio Inc (NASDAQ: PASG )(IPOed Friday) Syneos Health Inc (NASDAQ: SYNH ) Trillium Therapeutics Inc (NASDAQ: TRIL )(moved in sympathy with Forty Seven, as it has a similar drug in the pipeline for solid tumor) Zynex Inc. (NASDAQ: ZYXI ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 2) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Akorn, Inc. (NASDAQ: AKRX ) ANI Pharmaceuticals Inc (NASDAQ: ANIP )(moved lower despite FDA nod for a generic version of Teva Pharmaceutical Industries Ltd's (NYSE: TEVA ) Alzheimer's related dementia drug) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) (reacted to its fourth-quarter results) Evolus Inc (NASDAQ: EOLS ) EXACT Sciences Corporation (NASDAQ: EXAS ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Imv Inc (NASDAQ: IMV ) Neurometrix Inc (NASDAQ: NURO ) Portola Pharmaceuticals Inc (NASDAQ: PTLA ) Precigen Inc (NASDAQ: PGEN ) Taro Pharmaceutical Industries Ltd. (NYSE: TARO ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) TherapeuticsMD Inc (NASDAQ: TXMD ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Viking Therapeutics Inc (NASDAQ: VKTX ) Related Link: How The COVID-19 Outbreak Is Benefiting Biotech Investors Stocks In Focus GenMark Starts Shipping COVID-19 Test Kits GenMark said it has begun shipping ePlex Research Use Only, or RUO, test kits to detect COVID-19 virus.
   Viking Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update  2020/02/26 21:15:00 PR Newswire
/PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for…
   The future of these 7 biotechs hinges on their ability to treat a silent liver disease and capture a $9.6 billion market. Here's exactly what investors should be watching for this year.  2020/02/25 18:19:00 Business Insider
There are about 70 drugs in clinical testing for NASH, a fatty liver disease that affects millions of Americans and is a top cause of liver transplants. We identified seven biotechs that have staked their companies — and their stocks — on finding success in NASH in 2020. Those seven are: Intercept Pharmaceuticals, Genfit, NGM Biopharmaceuticals, Akero Therapeutics, Viking Therapeutics, Inventiva Pharma, and 89bio 2019 crumbled into a "graveyard of failures" in NASH, as one Wall Street analyst put it. But the small biotech Intercept stood alone in success. Now, the company has to convince regulators to approve its drug, which would be the first-ever NASH treatment. The other six biotechs we highlight have major clinical trial readouts set for 2020, which could prove transformative for these companies in the hunt for additional NASH therapies. Click here for more BI Prime stories . Big drugmakers have faced years of costly failures in the fight to come up with treatments for the silent liver disease known as NASH.

calendar